RT Journal Article
SR Electronic
T1 Using machine learning and centrifugal microfluidics at the point-of-need to predict clinical deterioration of patients with suspected sepsis within the first 24 h
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.10.08.24314844
DO 10.1101/2024.10.08.24314844
A1 Malic, Lidija
A1 Zhang, Peter G.Y.
A1 Plant, Pamela
A1 Clime, Liviu
A1 Nassif, Christina
A1 Fonte, Dillon Da
A1 Haney, Evan E.
A1 Moon, Byeong-Ui
A1 Sit, Victor
A1 Brassard, Daniel
A1 Mounier, Maxence
A1 Churcher, Eryn
A1 Tsoporis, James T.
A1 Falsafi, Reza
A1 Bains, Manjeet
A1 Baker, Andrew
A1 Trahtemberg, Uriel
A1 Lukic, Ljuboje
A1 Marshall, John C.
A1 Geissler, Matthias
A1 Hancock, Robert E.W.
A1 Veres, Teodor
A1 dos Santos, Claudia C.
YR 2024
UL http://medrxiv.org/content/early/2024/10/28/2024.10.08.24314844.abstract
AB Sepsis is the body’s dysfunctional response to infection associated with organ failure. Delays in diagnosis have a substantial impact on survival. Herein, samples from 586 in-house patients were used in conjunction with machine learning and cross-validation to narrow a gene expression signature of immune cell reprogramming to predict clinical deterioration in patients with suspected sepsis within the first 24 hours (h) of clinical presentation using just six genes (Sepset). The accuracy of the test (∼90% in early intensive care unit (ICU) and 70% in emergency room patients) was validated in 3,178 patients from existing independent cohorts. A real-time reverse transcriptase polymerase chain reaction (RT-PCR)-based test was shown to have a 98% sensitivity in >230 patients to predict worsening of the sequential organ failure scores or admission to the ICU within the first 24 h following Sepset detection. A stand-alone centrifugal microfluidic instrument that integrates the entire automated workflow for detection of the Sepset classifier in whole blood using digital droplet PCR was developed and tested. This PREcision meDIcine for CriTical care (PREDICT) system had a high sensitivity of 92%, specificity of 89%, and an overall accuracy of 88% in identifying the risk of imminent clinical deterioration in patients with suspected sepsis.Description of Graphic AbstractFeature reduction and development of a gene classifier that predicts deterioration-risk-groups in patients starts with in-house RNA sequencing data from patient collected from a heterogenous cohort of patients with suspected sepsis (top left) to reduce our original published gene signature down to 6-genes (Sepset), for which expression could be related to 2 housekeeping genes. Feature selection was performed using machine learning (ML) and AI and the classifier validated in samples from published transcriptomic studies. Molecular assay is then developed by designing and testing primer/probe sequences specific to the target genes using digital droplet PCR. In parallel, sample-to-answer microfluidic platform and cartridges are developed (bottom right) and analytical performance of multiplex quantitative assay is tested. Prognostic enrichment is obtained by analyzing the results using ML algorithm to determine the percent likelihood of significant clinical deterioration within the immediate next 24 h. The deployment of PREDICT platform (center) at the point-of-care is anticipated to aid in triage and management of prospective sepsis within the first 3 h of clinical presentation.Competing Interest StatementConflicts of Interest REWH is an inventor of the Sepset signature that has been patented in 17 countries (e.g. US patent 11,851,717 issued Dec 26, 2023) and is CEO and a shareholder of Asep Medical and its subsidiary Sepset BioSciences Inc. that have licensed in these patents and are actively commercially developing sepsis diagnostics. REWH also has a contract from Sepset Biosciences for development of diagnostic assays for adult sepsis. PGYZ and EFH are employees of Sepset Biosciences Inc. and/or Asep Medical. Clinical Protocolshttps://clinicaltrials.gov/study/NCT04747782?tab=resultsFunding StatementFunding statement included in manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Unity Health Toronto REB approvalI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPreviously published data can be obtained from GEO. Data from internal validation cohort can be obtained upon request